Serotonin receptor subtypes: functional, physiological, and clinical correlates

PL Bonate - Clinical neuropharmacology, 1991 - journals.lww.com
Serotonin (5-hydroxytryptamine, 5-HT) is one of the newer neurotransmitters to be
recognized for physiological importance. What is meant by"'newer''is that the majority of work …

Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients

A Amery, R Fagard, R Fiocchi, P Lijnen… - Journal of …, 1984 - journals.lww.com
Abstract Ketanserin (3× 40 mg daily) was administered during 6 weeks in 14 patients with
mild to moderate essential hypertension using a double-blind, placebo-controlled, crossover …

[引用][C] Ketanserin—a novel antihypertensive drug?

PPA Humphrey, W Feniuk… - Journal of Pharmacy and …, 1982 - academic.oup.com
There is a current controversy in the literature about the mechanism of the hypotensive
action of the new 5-hydroxytryptamine antagonist, ketanserin. The advocates of the drug …

[HTML][HTML] Serotonergic modulation of neurovascular transmission: A focus on prejunctional 5-HT receptors/mechanisms

A González-Hernández, BA Marichal-Cancino… - Biomedicines, 2023 - mdpi.com
5-Hydroxytryptamine (5-HT), or serotonin, plays a crucial role as a neuromodulator and/or
neurotransmitter of several nervous system functions. Its actions are complex, and depend …

Lowering of blood pressure by direct-and indirect-acting serotonin agonists in spontaneously hypertensive rats

RW Fuller, TT Yen, NB Stamm - Clinical and Experimental …, 1981 - Taylor & Francis
l-(m-Trifluoromethylphenyl) piperazine, a serotonin agonist, lowered blood pressure in
spontaneously hypertensive rats (SHR) at doses of 2 to 10 mg/kg sc A structurally related …

5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT).

W Ni, SW Watts - Clinical & Experimental Pharmacology & …, 2006 - search.ebscohost.com
The function of the serotonin transporter (SERT) is to take up and release serotonin (5-
hydroxytyptamine (5-HT)) from cells and this function of SERT in the central nervous system …

Ketanserin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease

RN Brogden, EM Sorkin - Drugs, 1990 - Springer
Ketanserin is a 5-HT 2 receptor antagonist without partial agonist properties which also
possesses weak α 1-adrenoceptor antagonistic activity, which may explain its …

Serotonin-S2 receptor binding sites and functional correlates

JE Leysen, DDC De Courcelles, F De Clerck… - …, 1984 - Elsevier
Serotonin-S 2 receptor binding sites have been labelled with several ligands such as [3 H]
spiperone,[3 H] lysergic acid diethylamide (LSD),[3 H] mianserin and [3 H] ketanserin, the …

5-hydroxytryptamine and vascular disease.

PM Vanhoutte - Federation proceedings, 1983 - europepmc.org
The release of 5-hydroxytryptamine (5-HT) from aggregating platelets may trigger acute
vasospastic episodes of larger arteries, which can lead to tissue ischemia, particularly in the …

Cardiovascular effects from stimulation of 5‐hydroxytryptamine receptors

PR Saxena - Fundamental & clinical pharmacology, 1989 - Wiley Online Library
The cardiovascular effects of 5‐hydroxytryptamine (5‐HT), consisting of bradycardia or
tachycardia, hypotension or hypertension, and vasodilatation or vasoconstriction, are …